sibutramine hydrochloride
CLINICAL USE
Treatment of obesity for patients who have not responded to appropriate weight reducing methods
DOSE IN NORMAL RENAL FUNCTION
10–15 mg daily
PHARMACOKINETICS
Molecular weight :334.3 %Protein binding :97 %Excreted unchanged in urine : Only inactive metabolites Volume of distribution (L/kg) :No datahalf-life – normal/ESRD (hrs) :14–16 DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50 : Dose as in normal renal function. Use with caution 10 to 20 : Dose as in normal renal function. Use with caution <10 : Dose as in normal renal function. Use with caution DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD :Unlikely to be dialysed. Dose as in GFR <10 mL/min HD :Unlikely to be dialysed. Dose as in GFR <10 mL/minHDF/high flux :Unknown dialysability. Dose as in GFR <10 mL/minCAV/VVHD :Unknown dialysability. Dose as in GFR 10 to 20 mL/min IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsAntidepressants: increased risk of CNS toxicity; avoid concomitant administration with MAOIs and moclobemide – avoid for at least 2 weeks after stopping sibutramine; increased CNS toxicity with noradrenaline re-uptake inhibitors, tricyclics, SSRIs, mirtazapine and tryptophan – avoid concomitant use with tryptophanAntipsychotics: increased risk of CNS toxicity – avoid concomitant useAvoid use with drugs which increase heart rate or blood pressure ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
Do not use in patients with uncontrolled hypertension, i.e. BP >145/90 mmHgInitiation of therapy is associated with a mean increase in resting systolic and diastolic BP of 2–3 mmHg
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home
.JPG)